CompletedPhase 2NCT01630083
Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer
Studying NON RARE IN EUROPE: Adenocarcinoma of stomach
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Astellas Pharma Global Development, Inc.
- Principal Investigator
- Executive DirectorAstellas Pharma Global Development, Inc.
- Intervention
- epirubicin(drug)
- Enrollment
- 252 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2012 – 2019
Study locations (30)
- Site BUL004, Plovdiv, Bulgaria
- Site BUL001, Sofia, Bulgaria
- Site BUL003, Sofia, Bulgaria
- Site BUL005, Sofia, Bulgaria
- Site BUL002, Varna, Bulgaria
- Site CZE002, Olomouc, Czechia
- Site CZE001, Znojmo, Czechia
- Site GER012, Bielefeld, Germany
- Site GER029-01, Bochum, Germany
- Site GER029, Bochum, Germany
- Site GER010, Dresden, Germany
- Site GER001, Essen, Germany
- Site GER017, Frankfurt, Germany
- Site GER005, Halle, Germany
- Site GER020, Leipzig, Germany
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01630083 on ClinicalTrials.govOther trials for NON RARE IN EUROPE: Adenocarcinoma of stomach
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07431281Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2AstraZeneca
- ACTIVE NOT RECRUITINGNCT07448493Local Treatment Strategies for Brain Metastases of Gastric and Esophageal CancerBlokhin's Russian Cancer Research Center
- RECRUITINGPHASE1, PHASE2NCT07262619EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) TumorsEikon Therapeutics
- RECRUITINGPHASE2NCT07070466Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEAMassachusetts General Hospital
- RECRUITINGPHASE2NCT07102901Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction AdenocarcinomaJiangsu HengRui Medicine Co., Ltd.
- RECRUITINGPHASE2NCT07212933The Safety and Clinical Efficacy of RAK Cell Therapy in Late-stage Gastric Cancer: A Randomized Controlled TrialChinese PLA General Hospital
- RECRUITINGNCT07032961A Cohort Study of Mobile Capsule Gastroscopy for Gastric Pathologies ScreeningNanfang Hospital, Southern Medical University
- RECRUITINGPHASE1, PHASE2NCT06710756Lead-212 PSV359 Therapy for Patients With Solid TumorsPerspective Therapeutics
See all trials for NON RARE IN EUROPE: Adenocarcinoma of stomach →